Phase II study of tauromustine in malignant glioma
(1992) In European Journal of Cancer 28(12). p.1959-1962- Abstract
46 eligible patients with either anaplastic astrocytoma (AA) or glioblastoma (GBM) and clinical and computed-tomography-confirmed relapse following primary surgery and radiotherapy received oral tauromustine 130 mg/m2 every 5 weeks. A prospective design allowed for concurrent assessment of both clinical and radiological responses and drug toxicity. 41% of patients improved clinically whilst 46% improved radiologically with 3 complete, 7 partial and 7 minimal responses (WHO criteria). Toxicity included grade III or IV gastrointestinal side-effects (15%), grade III or IV leukopenia (24%) and grade III and IV thrombocytopenia (44%). In 9 clinically responding patients, haematological toxicity led to discontinuation of treatment. All... (More)
46 eligible patients with either anaplastic astrocytoma (AA) or glioblastoma (GBM) and clinical and computed-tomography-confirmed relapse following primary surgery and radiotherapy received oral tauromustine 130 mg/m2 every 5 weeks. A prospective design allowed for concurrent assessment of both clinical and radiological responses and drug toxicity. 41% of patients improved clinically whilst 46% improved radiologically with 3 complete, 7 partial and 7 minimal responses (WHO criteria). Toxicity included grade III or IV gastrointestinal side-effects (15%), grade III or IV leukopenia (24%) and grade III and IV thrombocytopenia (44%). In 9 clinically responding patients, haematological toxicity led to discontinuation of treatment. All patients were followed-up until death and second-line chemotherapy was not used. Median post-treatment survival was 26 weeks for patients with GBM and 57 weeks for patients with AA. Overall 2-year survival rate was 69% for AA and 23% for GBM. Tauromustine given at the time of relapse has demonstrable antitumour activity in patients not previously treated with chemotherapy.
(Less)
- author
- Gregor, A ; Rampling, R ; Aapro, Matti ; Malmström, Per LU ; Whittle, I R ; Rye, R ; Stewart, M ; Sellar, R ; Demierre, B and Ironside, J W
- publishing date
- 1992
- type
- Contribution to journal
- publication status
- published
- keywords
- Adult, Antineoplastic Agents/therapeutic use, Astrocytoma/drug therapy, Brain Neoplasms/drug therapy, Drug Administration Schedule, Drug Evaluation, Female, Glioma/drug therapy, Humans, Leukopenia/chemically induced, Male, Middle Aged, Nausea/chemically induced, Nitrosourea Compounds/adverse effects, Prospective Studies, Taurine/adverse effects, Thrombocytopenia/chemically induced
- in
- European Journal of Cancer
- volume
- 28
- issue
- 12
- pages
- 4 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:0026666566
- pmid:1419289
- ISSN
- 0959-8049
- DOI
- 10.1016/0959-8049(92)90236-u
- language
- English
- LU publication?
- no
- id
- 7dea0071-19dc-40d1-9e45-398e00b30107
- date added to LUP
- 2022-03-01 08:51:05
- date last changed
- 2024-01-03 08:52:58
@article{7dea0071-19dc-40d1-9e45-398e00b30107,
abstract = {{<p>46 eligible patients with either anaplastic astrocytoma (AA) or glioblastoma (GBM) and clinical and computed-tomography-confirmed relapse following primary surgery and radiotherapy received oral tauromustine 130 mg/m2 every 5 weeks. A prospective design allowed for concurrent assessment of both clinical and radiological responses and drug toxicity. 41% of patients improved clinically whilst 46% improved radiologically with 3 complete, 7 partial and 7 minimal responses (WHO criteria). Toxicity included grade III or IV gastrointestinal side-effects (15%), grade III or IV leukopenia (24%) and grade III and IV thrombocytopenia (44%). In 9 clinically responding patients, haematological toxicity led to discontinuation of treatment. All patients were followed-up until death and second-line chemotherapy was not used. Median post-treatment survival was 26 weeks for patients with GBM and 57 weeks for patients with AA. Overall 2-year survival rate was 69% for AA and 23% for GBM. Tauromustine given at the time of relapse has demonstrable antitumour activity in patients not previously treated with chemotherapy.</p>}},
author = {{Gregor, A and Rampling, R and Aapro, Matti and Malmström, Per and Whittle, I R and Rye, R and Stewart, M and Sellar, R and Demierre, B and Ironside, J W}},
issn = {{0959-8049}},
keywords = {{Adult; Antineoplastic Agents/therapeutic use; Astrocytoma/drug therapy; Brain Neoplasms/drug therapy; Drug Administration Schedule; Drug Evaluation; Female; Glioma/drug therapy; Humans; Leukopenia/chemically induced; Male; Middle Aged; Nausea/chemically induced; Nitrosourea Compounds/adverse effects; Prospective Studies; Taurine/adverse effects; Thrombocytopenia/chemically induced}},
language = {{eng}},
number = {{12}},
pages = {{1959--1962}},
publisher = {{Elsevier}},
series = {{European Journal of Cancer}},
title = {{Phase II study of tauromustine in malignant glioma}},
url = {{http://dx.doi.org/10.1016/0959-8049(92)90236-u}},
doi = {{10.1016/0959-8049(92)90236-u}},
volume = {{28}},
year = {{1992}},
}